These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38806524)

  • 1. Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis.
    Burian K; Heidler F; Frahm N; Hecker M; Langhorst SE; Mashhadiakbar P; Streckenbach B; Baldt J; Meißner J; Richter J; Zettl UK
    Sci Rep; 2024 May; 14(1):12248. PubMed ID: 38806524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Zettl UK; Richter J
    Eur Neurol; 2022; 85(2):104-111. PubMed ID: 34743082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Burian K; Zettl UK; Richter J
    Sci Rep; 2022 Sep; 12(1):15147. PubMed ID: 36071083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021.
    Ehde DM; Roberts MK; Humbert AT; Herring TE; Alschuler KN
    Mult Scler Relat Disord; 2021 Sep; 54():103163. PubMed ID: 34325399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine hesitancy among people with multiple sclerosis.
    Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
    Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study.
    Werner F; Zeschick N; Kühlein T; Steininger P; Überla K; Kaiser I; Sebastião M; Hueber S; Warkentin L
    BMC Med; 2023 Sep; 21(1):358. PubMed ID: 37726711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. People's Willingness to Vaccinate Against COVID-19 Despite Their Safety Concerns: Twitter Poll Analysis.
    Eibensteiner F; Ritschl V; Nawaz FA; Fazel SS; Tsagkaris C; Kulnik ST; Crutzen R; Klager E; Völkl-Kernstock S; Schaden E; Kletecka-Pulker M; Willschke H; Atanasov AG
    J Med Internet Res; 2021 Apr; 23(4):e28973. PubMed ID: 33872185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States.
    Ehde DM; Roberts MK; Herring TE; Alschuler KN
    Mult Scler Relat Disord; 2021 Apr; 49():102788. PubMed ID: 33508570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.
    Labani A; Chou S; Kaviani K; Ropero B; Russman K; Becker D
    Mult Scler Relat Disord; 2023 Sep; 77():104865. PubMed ID: 37418929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey.
    Gaur P; Agrawat H; Shukla A
    Rheumatol Int; 2021 Sep; 41(9):1601-1605. PubMed ID: 34213580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing education: Personal communication with a healthcare professional is a critical step to address vaccine hesitancy for people with multiple sclerosis.
    Panisset MG; Kilpatrick T; Cofré Lizama LE; Galea MP
    Mult Scler Relat Disord; 2022 Jul; 63():103933. PubMed ID: 35671672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases: A Longitudinal Analysis.
    Duculan R; Mancuso CA
    J Clin Rheumatol; 2022 Jun; 28(4):190-195. PubMed ID: 35067512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
    Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
    Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events.
    Pergent M; Haerynck F; Hoste L; Gardulf A
    Front Immunol; 2023; 14():1166198. PubMed ID: 37143673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with SARS-CoV-2 vaccine hesitancy after stroke: a cross-sectional study.
    Hu P; Zhu YH; Bai CC; Wang W; Li D; Cao L; Huang YQ; Heng T; Zhou XH; Liu T; Luo YX; Yao XQ
    BMC Public Health; 2024 May; 24(1):1401. PubMed ID: 38797861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.